ALPS Medical Breakthroughs ETF (SBIO) |
| 67.09 -2.42 (-3.48%) 08-28 16:00 |
| Open: | 69.15 |
| High: | 69.15 |
| Low: | 67 |
| Volume: | 31,616 |
| Market Cap: | 213(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 82.75 |
| Resistance 1: | 70.85 |
| Pivot price: | 68.45 |
| Support 1: | 65.75 |
| Support 2: | 62.60 |
| 52w High: | 70.85 |
| 52w Low: | 34.88 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 12 Aug 2026
Behavioral Patterns of SBIO and Institutional Flows - Stock Traders Daily
Thu, 09 Jul 2026
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)? - Yahoo Finance
Tue, 07 Jul 2026
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn (NYSEARCA:SBIO) - Seeking Alpha
Thu, 02 Jul 2026
Biotech stocks boost ALPS Medical Breakthroughs... - Pluang
Thu, 02 Jul 2026
Biotech Gives SBIO Its Best Month Since 2023 - ETF Database
Thu, 25 Jun 2026
Biotech ETF Index Surges 10% After Rebalance - ETF Database
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
